Beta-Cell Function After Near-Normalisation of Blood Glucose
Not Applicable
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: glucagon-like peptide-1,Drug: SalineDrug: glucose dependent insulinotropic polypeptide
- Registration Number
- NCT00612950
- Lead Sponsor
- Hvidovre University Hospital
- Brief Summary
The incretin effect is attenuated in patients with type 2 diabetes mellitus partly due to impaired potentiation of beta-cell responsiveness to glucose by glucose dependent insulinotropic polypeptide and glucagon-like peptide-1 respectively. The aim of the present study was to investigate whether 4 weeks of near-normalization of blood glucose could improve the insulin responses to GIP and GLP-1 in patients with type 2 diabetes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria
- Age 18-70 years
- Type 2 diabetes diagnosed after 30 years of age
- BMI > 25
Exclusion Criteria
- Severe complications to diabetes
- Abnormal liver and kidney function
- Haemoglobin below the lower limit
- Macroalbuminuria
- Systemic disease
- Pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description GLP-1 glucagon-like peptide-1, - saline Saline - GIP glucose dependent insulinotropic polypeptide -
- Primary Outcome Measures
Name Time Method 2.phase insulin response measured as incremental area under the curve from 10-120 minutes 2 hours
- Secondary Outcome Measures
Name Time Method 2.phase insulin response measured as incremental area under the curve from 10-120 minutes, after 4 weeks of insulin treatment 2 hours
Trial Locations
- Locations (1)
Dept. of Endocrinology, Hvidovre Hospital
🇩🇰Copenhagen, Denmark